SLBST PHARMA

About SLBST Pharma

Endometriosis impacts one-in-ten women with crippling pain and infertility -- that's 7 million mothers, wives, sisters and daughters. There are no effective treatments.     

Our research has uncovered a known immunomodulator, in use for decades, with a strong safety profile, including during pregnancy. It shows promise in clinical studies, as the first effective treatment for endometriosis.

We have issued and pending patents for our repurposed drug. We anticipate a cost-effective treatment, with a robust margin, driven by low cost of goods.

We have a green light from FDA to proceed with a Phase 2 dose-finding study.